We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Laboratory-Developed Tests Market Driven by Cancer Treatment

By LabMedica International staff writers
Posted on 28 Nov 2017
The global market for laboratory-developed tests (LDTs) is estimated to be worth USD 13.2 billion and will grow by nearly 10% annually, driven mainly by oncology tests which will grow 60% faster than other types of LDTs. More...
These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

The trend of tests produced in a lab or sold commercially as a test service product is growing. Laboratories continue to develop and use LDTs due to the commercial unavailability of clinical needs for LDTs for assays. LDTs were historically low-volume, simple and well characterized tests for low-risk diagnostic applications. Of late, complex LDTs based on technologies such as next generation sequencing have become available for new applications, including oncology.

Currently, oncology is a large segment of the clinical LDT market, in terms of revenue. Several tests have been developed for diagnosis, predicting prognosis, providing information to aid in determining the best treatment for an individual patient, and for monitoring treatment – all aspects of personalized medicine in cancer. Another significant application and market segment is predicting the risk of hereditary cancer. Additionally, new tests have been introduced for screening apparently healthy individuals for cancer, and the cancer screening market is growing at a very rapid pace.

"Cancer treatment is driving this test market, and LDTs are more important, and profitable in cancer testing than any other area," said Bruce Carlson, Publisher of Kalorama Information.

However, the increasing visibility, complexity, and risk of LDT for certain applications, such as oncology have attracted calls for increased regulation of the market. Any sudden changes to the market, such as an abrupt requirement for all LDTs to meet stringent regulations or be removed from the market, could potentially result in several essential clinical tests becoming unavailable. This has raised significant concerns over the potential future changes in the regulation of LDTs, including FDA regulation of LDTs.

"This is a very crowded market. Not all companies will succeed," said Lucy Sannes of Sannes & Associates, who authored the report.

Related Links:
Kalorama Information


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Automated Cell Culture Chemistry Analyzer
BioProfile FLEX2 Basic
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.